G2S2 Capital Sells 50,000 Shares in Knight Therapeutics-February 2024-www.financetom.com

G2S2 Capital Sells 50,000 Shares in Knight Therapeutics

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

G2S2 Capital Sells 50,000 Shares in Knight Therapeutics

Mar 21, 2025 4:21 AM

07:10 AM EDT, 03/21/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) overnight Thursday said G2S2 Capital sold 50,000 Knight shares through the Toronto Stock Exchange at $6.40 each.

The disposal lowers G252's stake in Knight Therapeutics ( KHTRF ) to just above 10%.

Previous page： Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics Next page： Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Sep 15, 2025

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics ( GLUE ) signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will receive an upfront payment of $120 million and could earn up to $5.7 billion in total, including milestone payments...

Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong

Sep 15, 2025

07:17 AM EDT, 09/15/2025 (MT Newswires) -- Ocugen ( OCGN ) said Monday it has signed an exclusive licensing agreement with Kwangdong Pharmaceutical for the rights to commercialize its experimental gene therapy, OCU400, for the treatment of retinitis pigmentosa in South Korea. Under the deal, Ocugen ( OCGN ) said it will receive up to $7.5 million in upfront and...

Market Chatter: Apollo, Silver Point Capital Lead $900 Million Loan to Vantage Specialty Chemicals

Sep 15, 2025

07:16 AM EDT, 09/15/2025 (MT Newswires) -- Apollo Global Management ( APO ) and Silver Point Capital led a nearly $900 million direct loan to Vantage Specialty Chemicals to replace its current bank-arranged financing, Bloomberg News reported Friday, citing people with knowledge of the matter. Oak Hill Advisors also assisted with the funding, the news outlet reported, citing one of...

USA Compression Partners Plans to Offer $750 Million Senior Notes Due 2033 in Private Placement

Sep 15, 2025

07:42 AM EDT, 09/15/2025 (MT Newswires) -- USA Compression Partners ( USAC ) said Monday it plans to offer, together with its USA Compression Finance unit, $750 million of senior unsecured notes due 2033 in a private placement to eligible buyers. The company said it will use the net proceeds, along with borrowings under its credit agreement, to redeem all...